Bedel Financial Consulting’s Anavex Life Sciences AVXL Stock Holding History

Bedel Financial Consulting’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,210	Closed	-$15K	–	249
2022 Q1	$15K	Hold	1,210	–	–	﹤0.01%	590
2021 Q4	$21K	Hold	1,210	–	–	0.01%	552
2021 Q3	$22K	Hold	1,210	–	–	0.01%	531
2021 Q2	$28K	Hold	1,210	–	–	0.01%	487
2021 Q1	$18K	Hold	1,210	–	–	0.01%	527
2020 Q4	$7K	Hold	1,210	–	–	﹤0.01%	603
2020 Q3	$6K	Hold	1,210	–	–	﹤0.01%	581
2020 Q2	$6K	Hold	1,210	–	–	﹤0.01%	551
2020 Q1	$4K	Hold	1,210	–	–	﹤0.01%	594
2019 Q4	$3K	Hold	1,210	–	–	﹤0.01%	626
2019 Q3	$4K	Hold	1,210	–	–	﹤0.01%	585
2019 Q2	$4K	Hold	1,210	–	–	﹤0.01%	587
2019 Q1	$4K	Hold	1,210	–	–	﹤0.01%	589
2018 Q4	$2K	Hold	1,210	–	–	﹤0.01%	601
2018 Q3	$3K	Hold	1,210	–	–	﹤0.01%	586
2018 Q2	$3K	Hold	1,210	–	–	﹤0.01%	587
2018 Q1	$3K	Buy	+1,210	New	+$3.42K	﹤0.01%	586

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Bedel Financial Consulting's AVXL Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Anavex Life Sciences (AVXL) in Q2 2022, closing a stake of 1,210 shares — an estimated $15K sold.

Bedel Financial Consulting first reported a position in AVXL in Q1 2018 and held it in 17 quarters. The position peaked at $28K in Q2 2021. 150 funds tracked by Wall St. Rank hold AVXL as of Q2 2022.

Bedel Financial Consulting reported no remaining Anavex Life Sciences position as of Q2 2022 after selling out during the quarter.
Bedel Financial Consulting sold 1,210 Anavex Life Sciences shares in Q2 2022, an estimated $15K.
Bedel Financial Consulting first reported a position in Anavex Life Sciences in Q1 2018 and held it in 17 quarters.
Bedel Financial Consulting's Anavex Life Sciences position peaked at $28K in Q2 2021.
150 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.